Barclays lowered the firm’s price target on Zimmer Biomet (ZBH) to $105 from $112 and keeps an Underweight rating on the shares. The firm adjusted the company’s model into the Q3 report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Notable companies reporting before tomorrow’s open
- ZBH Upcoming Earnings Report: What to Expect?
- Zimmer Biomet: FDA grants BDD for iodine-treated total hip replacement system
- Zimmer Biomet: FDA grants BDD for treated total hip replacement system
- Zimmer Biomet’s Knee System Study: A Potential Game-Changer in Orthopedics